Accueil

La principale fonction du Groupe Dépistage du CIRC consiste à produire des données sur l'exactitude, la reproductibilité, l'efficacité, les avantages, les effets néfastes et la rentabilité de diverses interventions de dépistage précoce pour les cancers du sein, du col utérin, et pour les cancers colorectal et buccal, entre autres, en faisant baisser la mortalité et en améliorant la qualité de vie des patients dans différents contextes. Ces données peuvent ensuite être utilisées pour informer et améliorer l'utilisation rationnelle des ressources de soins de santé. L'objectif ultime du Groupe est de guider l'élaboration de politiques de santé publique pour la mise en œuvre du dépistage dans divers contextes de soins de santé, notamment dans les pays à revenu faible ou intermédiaire (PRFI).

Le Groupe SCR mène des études de terrain dans les PRFI pour évaluer diverses méthodes de détection précoce dans la lutte contre les cancers du sein, du col utérin, et les cancers colorectal et buccal. Ces initiatives visent aussi à identifier la façon dont les services de dépistage pourraient être intensifiés par le biais des services de santé publique au niveau local. Le Groupe développe diverses ressources de formation pour catalyser et renforcer les capacités en étroite collaboration avec les institutions nationales et les services de santé du gouvernement. Grâce à son programme de recherche, le Groupe apporte des bases scientifiques factuelles pour soutenir l'élaboration de politiques de détection précoce et de systèmes de santé appropriés pour la prestation de services primaires efficaces. Par exemple, le Groupe a contribué de manière significative à l'évaluation de l'innocuité et de l'efficacité d’un régime de moins de trois doses du vaccin contre le VPH pour la protection contre le cancer du col de l'utérus.


Actualité

EMERGENCY: Coronavirus disease (COVID-19) Pandemic

16/03/2020
Regular updates on the coronavirus disease (COVID-19) outbreak are available at the WHO website.

Launch of online learning programme on “Improving the Quality of Cancer Screening”

08/02/2021
We are pleased to announce the launch of a new freely accessible and modular resource on cancer screening and early diagnosis. This self-paced online learning programme was developed in the framework of the Cancer Screening in Five Continents (CanScreen5) project. This course was developed with the support of the American Cancer Society, the Medical Research Council (United Kingdom), the Research Council of Norway, and the Centre for Global Health Inequalities Research (CHAIN) of Norway. This open access learning programme covers evidence-based knowledge and skills on “Improving the Quality of Cancer Screening” through a variety of educational resources through 3 modules: principles of cancer screening, planning and implementing a cancer screening programme, and quality of cancer screening programmes.
View the IARC news and join the learning programme

Virtual meeting: Europe’s path to eliminating cervical cancer on 5 February at 14:00 CET time

05/02/2021
Cervical cancer is a significant health problem in Europe. WHO Member States have collectively resolved to end needless suffering from a cancer that is preventable, curable and could be eliminated within a generation by adopting the global strategy to accelerate the elimination of cervical cancer as a public health problem in November 2020. The objective of this webinar organized by the Associations of the European Cancer Leagues in collaboration with UICC, MEP, European Commission DG Santé and IARC is to inform a wide audience of health stakeholders about the global strategy and discuss Europe’s role in taking global commitments forward and signalling the importance of cervical health to European Member States, Associated countries and beyond. View the agenda and join the meeting

New publication: Cross-sectional survey of the impact of the COVID-19 pandemic on cancer screening programmes in selected low- and middle-income countries: study from the IARC COVID-19 impact study group

04/02/2021
In this new article, published in the International Journal of Cancer, the IARC COVID-19 impact study group including scientists from IARC and representatives from 17 countries in charge of cancer screening programmes, conducted a study to assess the impact of the pandemic on cancer screening programmes in LMICs that have made significant efforts in the past few years to improve the organization of their screening programmes. Based on our best knowledge, our study is the first reporting on the impact of COVID-19 outbreak on cancer screening care continuum for a set of low- and middle-income countries spread across different continents and Human development index categories. The status of the cancer testing, diagnostic and treatment services, and challenges and the best practices adopted to face the crisis are described. Sharing such information will help LMICs to improve resilience of screening services. View the article

New commentary: Eliminating cervical cancer in the COVID-19 era

04/02/2021
The COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus, poses a clear and present danger to the health and well-being of populations. A new comment, published in Nature Cancer by Dr Ophira Ginsburg, Dr Partha Basu, Dr Sharon Kapambwe and Dr Karen Canfell, discuss its indirect impact on global cancer prevention and control efforts, particularly for cervical cancer. Authors suggest some comparisons between the COVID-19 pandemic and the human papillomavirus–induced cancer burden, as well as opportunities for translating pandemic-control strategies into effective cancer control. View the commentary

Toutes les actualités


Publications scientifiques

Xia C., Xu X., Zhao X., Hu S., Qiao Y., Zhang Y., Hutubessy R., Basu P., Broutet N., Jit M., Zhao F. Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study. BMC Med. 2021 Mar 3;19(1):62.
PMID: 33653331
Joshi S., Muwonge R., Kulkarni V., Lucas E., Kulkarni S., Kand S., Mandolkar M., Baig M., Wankhede S., Surwase K., Pardeshi D., Basu P., Rengaswamy S. Mobile Screening Unit (MSU) for the Implementation of the 'Screen and Treat' Programme for Cervical Cancer Prevention In Pune, India. Asian Pac J Cancer Prev. 2021 Feb 1;22(2):413-418.
PMID: 33639655
Mariz F.C., Bender N., Anantharaman D., Basu P., Bhatla N., Pillai M.R., Prabhu P.R., Sankaranarayanan R., Eriksson T., Pawlita M., Prager K., Sehr P., Waterboer T., Muller M., Lehtinen M. Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines. NPJ Vaccines. 2020 Feb 14;5(1):14.
PMID: 33580075

Toutes les publications scientifiques

IARC, 150 Cours Albert Thomas, 69372 Lyon CEDEX 08, France - Tel: +33 (0)4 72 73 84 85 - Fax: +33 (0)4 72 73 85 75
© CIRC 2021 - Terms of use  -  Politique de confidentialité.